By contrast, in ovarian cancer models, Zou and colleagues found that EZH2 inhibition did not alter class I antigen presentation of ovarian cancer cells, which indicates that the regulation of EZH2 on antigen presentation may be cancer-type specific [60]. This evidence concerns the gene EZH2 and cancer.